Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 2
2005 1
2007 1
2008 2
2009 1
2010 4
2011 3
2012 1
2013 1
2014 2
2015 4
2016 1
2017 4
2018 3
2019 5
2020 1
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hiret S, Dixmier A, Renault PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, Besse B. Cortot AB, et al. Among authors: dayen c. Eur J Cancer. 2020 May;131:27-36. doi: 10.1016/j.ejca.2020.02.022. Epub 2020 Apr 8. Eur J Cancer. 2020. PMID: 32276179 Clinical Trial.
[Endobronchial ultrasound (EBUS): the state of the art].
Douadi Y, Dayen C, Lachkar S, Fournier C, Thiberville L, Ramon P, François G, Jounieaux V. Douadi Y, et al. Among authors: dayen c. Rev Mal Respir. 2012 Apr;29(4):475-90. doi: 10.1016/j.rmr.2011.10.001. Epub 2012 Mar 26. Rev Mal Respir. 2012. PMID: 22542406 Review. French.
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, Muñiz-Castrillo S, Roger M, Raimbourg J, Dayen C, Grignou L, Pallix-Guyot M, Lannoy J, Ducray F, Desestret V, Psimaras D, Honnorat J. Vogrig A, et al. Among authors: dayen c. Neurol Neuroimmunol Neuroinflamm. 2019 Aug 7;6(6):e604. doi: 10.1212/NXI.0000000000000604. Print 2019 Nov. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31454760 Free PMC article.
[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M. Mignard X, et al. Among authors: dayen c. Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. Rev Mal Respir. 2018. PMID: 30243521 Free article. Clinical Trial. French.
[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].
Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M. Debieuvre D, et al. Among authors: dayen c. Rev Mal Respir. 2019 Jun;36(6):649-663. doi: 10.1016/j.rmr.2019.03.010. Epub 2019 Jun 14. Rev Mal Respir. 2019. PMID: 31204231 French.
[A pleural transudate with a 0 g/L protein level].
Trouve C, Le Meunier F, Solomalalarivelo F, Delentaigne Delogivieres X, Drouard M, Suguenot R, Lecuyer E, Bentayeb H, Rault I, Douadi Y, Dayen C. Trouve C, et al. Among authors: dayen c. Rev Mal Respir. 2015 May;32(5):535-8. doi: 10.1016/j.rmr.2014.07.011. Epub 2014 Sep 3. Rev Mal Respir. 2015. PMID: 26072010 French. No abstract available.
36 results